Asahi Kasei, a globally operating, diversified company, has announced that it will consolidate its manufacturing activities at the Mizushima site by fiscal year 2030.
This will have no immediate impact on the company’s range of derivative products. The business units within Asahi Kasei’s Materials Division affected by this initiative generated sales of 116.2 billion yen in fiscal year 2025. The Materials Division as a whole generated 1,306.2 billion yen during the same period. These measures are consistent with the previously announced [initiative/initiative/etc.].
Asahi Kasei Mitsubishi Chemical Ethylene (AMEC) had discontinued ethylene production and has further advanced the company’s efforts to increase capital efficiency and strengthen long-term profitability.
Asahi Kasei’s discontinuation of these derivatives and the realignment of its supply chain are part of a broader initiative to streamline the company’s materials portfolio and improve capital efficiency. The announced measures aim to withdraw from less profitable business areas and restructure the associated supply chains within global petrochemical markets.
Asahi Kasei expects this to result in improved margins while simultaneously optimizing capital allocation to strategic growth areas. Under its current management plan, “Trailblaze Together,” Asahi Kasei is improving capital efficiency and implementing structural reforms that focus resources on its key growth pillars: pharmaceuticals, critical care, housing, and semiconductor materials.
Recent actions include the signing of a framework agreement. with Mitsui Chemicals and Mitsubishi Chemical to promote the decarbonization of ethylene production in western Japan, as well as the acquisition of Aicuris Strengthening the specialty pharmaceutical platform in the area of serious infectious diseases underlines Asahi Kasei’s consistent implementation of this strategy and consolidates the foundation for sustainable, profitable growth.
